What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
His main research concerns Internal medicine, Surgery, Connective tissue disease, Immunology and Scleroderma.
Yannick Allanore has included themes like Gastroenterology and Cardiology in his Internal medicine study.
His study in Surgery is interdisciplinary in nature, drawing from both Pulmonary hypertension, Cohort and DLCO.
His work deals with themes such as Systemic disease, Autoantibody and Vascular endothelial growth factor, which intersect with Connective tissue disease.
In his study, which falls under the umbrella issue of Immunology, Odds ratio is strongly linked to Allele.
His biological study spans a wide range of topics, including Clinical trial, Microangiopathy, Rheumatism, Placebo-controlled study and Abatacept.
His most cited work include:
- 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative (1669 citations)
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database (658 citations)
- Early Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis A French Nationwide Prospective Multicenter Study (605 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Immunology, Scleroderma, Rheumatoid arthritis and Gastroenterology.
His studies deal with areas such as Surgery and Cardiology as well as Internal medicine.
He interconnects Fibrosis, Single-nucleotide polymorphism, Genotype and Allele in the investigation of issues within Immunology.
The Scleroderma study combines topics in areas such as Physical therapy, Clinical trial and Disease.
His Rheumatoid arthritis research is multidisciplinary, incorporating perspectives in Methotrexate, Rituximab and Arthritis.
His Connective tissue disease study combines topics from a wide range of disciplines, such as Systemic disease and Immunopathology.
He most often published in these fields:
- Internal medicine (58.50%)
- Immunology (22.54%)
- Scleroderma (18.25%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (58.50%)
- Interstitial lung disease (11.09%)
- Scleroderma (18.25%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Interstitial lung disease, Scleroderma, Disease and Gastroenterology are his primary areas of study.
His works in FEV1/FVC ratio, Cohort, Rheumatology, Rheumatoid arthritis and Vital capacity are all subjects of inquiry into Internal medicine.
His Interstitial lung disease course of study focuses on Clinical trial and Expert consensus.
His Scleroderma study also includes fields such as
- Fibrosis that intertwine with fields like Autoimmune disease, Inflammation and Pulmonary hypertension,
- Severity of illness, which have a strong connection to Prospective cohort study.
His Disease research includes elements of Gangrene and Intensive care medicine.
His Gastroenterology research incorporates elements of Odds ratio, Complication and Biomarker.
Between 2017 and 2021, his most popular works were:
- Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) (130 citations)
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial (66 citations)
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study (61 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Internal medicine, Interstitial lung disease, Scleroderma, Fibrosis and Randomized controlled trial are his primary areas of study.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Placebo.
The study incorporates disciplines such as Methotrexate and Rheumatology in addition to Interstitial lung disease.
His work carried out in the field of Scleroderma brings together such families of science as Disease, Cohort and Intensive care medicine.
His Fibrosis research is multidisciplinary, relying on both Inflammation, Immune system, Immunology, Survival analysis and Abatacept.
His research in Randomized controlled trial intersects with topics in Tocilizumab, Tolerability, Clinical trial and Systematic review.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
